Suzhou Connect Biopharmaceuticals, Ltd.
HomeحContact UsحSite Map
About Us
Management Team
Investors
Zheng Wei, Ph.D., Co-founder, CEO
    Dr. Zheng Wei has over 20 years of experience in the biopharmaceutical industry and 15 years in GPCR drug discovery and development. Prior to co-founding Suzhou Connect Biopharma, Dr. Zheng was Director of Immunology at Arena Pharmaceuticals where he oversaw the discovery programs in the inflammation therapeutic area. Prior to joining Arena, Dr Zheng was a founding scientist and Assistant Director of Biology at ChemoCentryx. During his 10 year tenure at ChemoCentryx, he was responsible for the invention and implementation of the companys proprietary technology platform; he initiated and led two drug discovery programs that yielded drug candidates that entered Phase II and Phase III clinical trials, including Vercirnon for inflammatory bowel disease (IBD) that was licensed to GSK. Prior to ChemoCentryx, he was a scientist at Ligand Pharmaceuticals. He also conducted research on human antibody gene rearrangement at Stanford University School of Medicine. Dr. Zheng is an inventor of 14 issued patents several pending patent applications on GPCR related therapeutic agents and technologies. He received his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis.
 
William (Wubin) Pan, Ph.D., Co-founder, President and Chairman of the Board
    Dr. Pan has over 20 years of experience in biosciences, especially biopharmaceutical R&D including more than 10 years in Europe and North America. Prior to co-founding Suzhou Connect Biopharma, he is Executive Vice President at Crown Bioscience, Inc., a US venture-backed US company with major operation in China (Beijing & Shanghai) providing CRO services to international biopharmaceutical companies. Dr. Pan co-founded CrownBio and served in several executive capacities including China President, Chief Operation Officer. Prior to co-founding Crown Bioscience, Dr. Pan was the Vice President at TsingHuaYuanXing Biopharmaceutical Co. Ltd. (Shenzhen, China) after he returned to China as an entrepreneur in 2000. Between 2001 and 2006, he co-founded and served as Vice President and/or General Manager for two other biotech companies, where he played key roles for the development of several gene-based therapeutic biologics and was involved in the development and successful marketing of several biomedical products. Dr. Pan obtained his Ph.D. in Biology in Sussex University (UK) and postdoctoral training at University of California at Berkeley. He holds a MBA from Tsing-Hua University.
 
Copyright: Suzhou Connect Biopharmaceuticals, Ltd.